Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    today
    Change Detected
    Summary
    Added a press release dated 09 March 2026 about Enhertu Priority Review for HER2-positive early breast cancer; removed the 20 January 2026 press release about completing a direct NYSE listing.
    Difference
    0.9%
    Check dated 2026-03-13T20:56:24.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    Added Feb 20, 2026 press release: Calquence plus venetoclax approved in the US for first-line chronic lymphocytic leukaemia. Removed Jan 8, 2026 press release announcing Joris Silon as Head of Investor Relations.
    Difference
    0.9%
    Check dated 2026-02-20T15:25:18.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Added two new press releases: Breztri Phase III KALOS/LOGOS results in The Lancet Respiratory Medicine (13 February 2026) and Full Year and Q4 2025 results (10 February 2026). Removed two older releases: Saphnelo self-administration TULIP-SC trial results (06 January 2026) and Enhertu Breakthrough Therapy Designation (22 December 2025).
    Difference
    5%
    Check dated 2026-02-13T12:37:43.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    New press releases have been added, including Datroway Priority Review, Saphnelo subcutaneous update, Imfinzi EU CHMP, NYSE listing, CSPC collaboration, and a $15B China investment. Older releases such as LATIFY trial update, Saphnelo EU subcutaneous pen approval, Enhertu/pertuzumab US first-line, ASH presence, and Baxdrostat FDA Priority Review have been removed.
    Difference
    5%
    Check dated 2026-02-05T23:56:23.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    Adds a new press release entry dated 29 January 2026 announcing AstraZeneca's plan to invest $15 billion in China through 2030 to pioneer the next generation of medicines.
    Difference
    0.5%
    Check dated 2026-01-29T18:49:31.000Z thumbnail image
  8. Check
    51 days ago
    Change Detected
    Summary
    Added 20 January 2026 entry: 'AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock Exchange'. Removed 21 November 2025 entry: 'AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalysing economic growth'.
    Difference
    0.9%
    Check dated 2026-01-22T09:27:31.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.